Sanofi, a French pharmaceutical company, will soon conclude an agreement on acquisition of the U.S. manufacturer of influenza vaccine, Protein Sciences, for $650 million, as it follows from the company’s a statement.
It is expected that the transaction will be closed in the third quarter of 2017.
In October 2016, Protein Sciences received permission to distribute in the USA a Flublok influenza vaccine made on the basis of recombinant protein. The speed of receiving such a vaccine is several times higher than the speed of production of vaccines based on chicken protein.
“The acquisition of Protein Sciences will allow us to expand the portfolio of influenza vaccines, particularly vaccines made without protein components of a chick embryo,” David Lowe, Vice President of Sanofi Pasteur, said.
